![](/static/6cc96789cab78bc4eecfb4898d9585de/6f6b3/hero-3-1.png)
Safety Profile
Adverse reactions that occurred in ≥5% of
deflazacort-treated patients and occurred more frequently than in placebo-treated patients3
- More boys taking deflazacort experienced cataracts compared with those taking prednisone (4.4% vs 1.6%). No cataracts were graded as serious adverse events.7
![Playing like a 6-year-old](/static/af3498f66aa8bad372201d1de4f2a580/91bda/section-3-1.png)
Guidelines recommend deflazacort as first-line therapy when there are pre-existing weight and/or behavioral issues or switching to deflazacort when weight gain and/or behavioral issues persist with prednisone5
Not anactual patient.